Background: Over the past decade, the volume of adverse events (AEs) reported to marketing authorization holders and regulators has been rapidly increasing each year, which has led to significant challenges in patient safety assessment. Three data sources that have largely contributed to the expansion in adverse event reports are patient support programs (PSPs), market research programs (MRPs), and social media. In this study, we sought to further understand the contribution of these safety data sources to the characterization of a product's safety profile. Methods: Three separate approaches were taken that, when combined, can be used to evaluate each data source. The first identified any core company data sheet changes or drug safety label changes. The second evaluated the similarity of information through proportions of AEs between each solicited data source and spontaneous sources. Lastly, the completeness of information reported was evaluated through vigiGrade and compared across each data source. Results: One drug safety label change was identified from a patient support program, which involved regular contact with health care providers. No label changes were identified from market research programs or social media. Patient support programs, market research programs, and social media report similar proportions for HLGT as spontaneous sources. Market research programs and social media display very low vigiGrade scores. When broken down by subtype, traditional PSPs display high vigiGrade scores, while patient assistance programs display lower vigiGrade scores that were program dependent. Conclusions: This study did not demonstrate that certain data sources such as market research programs, social media, and patient assistance programs meaningfully contributed to the further understanding of the characterization of a product's safety profile.
FAERS corresponding to over a 400% increase in a decade. 1 This situation of reports is leading to significant challenges in patient safety assessments, in terms of efficiency of processes and resourcing by MAHs and global regulatory bodies alike. The rise in number of adverse event reports is likely to be due to several factors, including new regulatory requirements, ease of reporting for both health care providers (HCPs) and patients or consumers, and increased adoption of digital technology. Although increasing public awareness and a reduction in underreporting of adverse events is welcomed, a better understanding of the relative contributions from each data source may further improve the knowledge of the adverse event profile of drugs.
Three specific data sources that have largely contributed to the expansion in adverse event reports are patient support programs (PSPs), market research programs (MRPs), and social media. PSP is a broad term, which covers numerous programs varying widely in purpose and design. Overall, they are MAH sponsored programs where the objective can vary from addressing product supply, specific reimbursement, access issues or even medical support. Some PSPs have organized safety data collection systems while other programs are not designed or intended to collect any pharmacovigilance data. In the PSP programs the MAH interacts, often through external service providers, directly with a patient care provider or consumer with 1 or more of the following purposes: helping patients manage their medications and/or disease outcome (eg, adherence, awareness, education), providing health care professionals with the support for their patients, and providing or arranging financial assistance for patients who cannot afford their medications in order to ensure treatment and improve compliance with treatment.
Much of the attention in the industry has centered on the intent of PSPs and how the information gathered from them should be used. While PSPs may involve contact with health care providers, patients or their caregivers, they do not include either a safety or efficacy endpoint. Nevertheless, there is a requirement to collect data on and assess adverse events and report (as applicable) suspected adverse drug reactions. In 1997, the FDA developed guidance for the pharmaceutical industry stating that adverse drug reactions reported from active solicitation should be treated as if from postmarketing studies for the purposes of expedited reporting-the focus of the guidance was on suspected, unexpected serious adverse reactions (SUSARs) and causality assessment by the manufacturer. 2 The Council for International Organizations of Medical Sciences (CIOMS) Working Group V subsequently took a similar approach 3 followed by ICH E2D 4 Volume 9A of the Rules Governing Medicinal Products in the European Union and subsequently Module VI of the Good Pharmacovigilance Practices (GVP) that superseded Volume 9A under the 2010 legislation. 5 Today, global regulations provide guidance that all adverse events collected from active solicitation programs should be treated as if from postmarketing studies, that is, warrant the reporting of SUSARs and thus requiring the collection, recording, and analysis of all individual cases. The key difference in the EU is the need to collect and report all serious and nonserious suspected ADRs from these solicited data sources. Furthermore, MAHs run a wide variety of PSP covering 1 or more purposes for which it does not appear appropriate to provide a single approach to adverse event collection. For example, some MAHs already distinguish between patient support programs and patient assistance programs (PAPs) where a PAP is defined as a project with the aim of patient assistance in the form of compensation, reimbursement, or access programs that is solely charitable in design, without the intent to collect information relating to the use of the medicinal product. Such a definition clearly challenges the concept that a PAP is a "study."
Market research programs have generally been included in the definition of a solicited data source in concert with PSPs and PAPs, yet MRPs have a different and distinct purpose, introducing a further layer of complexity. An MRP refers to the systematic collection, recording, and analysis by an MAH of data and findings about its medicinal products relevant for marketing and business development. Unlike PSPs, MRPs are not intended to assist patient care; however, adverse event information, incidentally mentioned during the course of an MRP, is expected per prevailing guidelines to be handled as solicited reports from "postmarketing studies."
The third safety information data source that has increasingly been the focus of interest in the industry in the past decade is social media. Social media includes websites and applications not under the control of the MAH that enable users to create and share content or to participate in social networking. Examples include Twitter, Facebook, LinkedIn, and Pinterest. This source has significantly expanded in use because of the rapid advancement and adoption of digital technology. Indeed, social media has the potential to facilitate the proliferation of safety information throughout the public domain. In September 2014, the Innovative Medicines Initiative (IMI) launched an initiative called Web-RADR to determine and develop the most appropriate use of social media and digital technologies in pharmaceutical research and development.
The increased use of these data sources in the pharmacovigilance system has raised the question as to the most appropriate use of each in signal detection. In this study of safety data across pharmaceutical companies (a subset of members of TransCelerate Biopharma i ), TransCelerate assessed several aspects of PSPs, PAPs, MRPs, and social media to provide additional clarity on this question. The findings of this research are intended to provide a further understanding of the contribution of these safety data sources to the characterization of a product's safety profile.
Materials and Methods

Data Source Definitions
A list of data sources was proposed by member companies and regulatory definitions were chosen and used wherever available (see Supplemental Material). In situations where more than one definition was available, the more detailed or conservative definition was chosen.
Three Pillars of Evidence
The goal of the analyses described in this study was to assess the relative contribution of PSPs, MRPs, and social media in the signal detection activities conducted with the purpose to improve the understanding of the safety profile of products following their commercialization. Three separate approaches were taken that when combined can be used to evaluate each data source. The first approach evaluated whether any valid or confirmed signals from these data sources resulted in core company data sheet changes or drug safety label changes. The second approach evaluated the similarity of information through proportions of AEs reported by MedDRA Higher Level Group Terms between each solicited data source and spontaneous sources. Lastly, the completeness of information reported was evaluated through the vigiGrade scoring method and compared across each data source. Each analysis was compiled and reviewed by a third-party management consultant contracted by TransCelerate to evaluate the rigor to which each company executed the 3 analyses, confirm the findings, and facilitate the execution of the study. Survey results and analyses that did not strictly adhere to the methods below were redone until adherence was verified by the third party.
Signal and Label Change Evaluation
A survey was developed by and distributed to TransCelerate member companies (see Supplemental Material). The intent of the survey was to identify whether any valid or confirmed signals solely arising from PSPs, PAPs, MRPs, or social media were identified and ultimately necessitated a change to the safety information on the product label from January 1, 2014, to December 31, 2016. Results were compiled by the thirdparty contracted by TransCelerate, blinded, aggregated, and summarized. Eleven companies responded to the survey. Findings from ongoing routine surveillance were also incorporated into this evaluation.
Similarity Analysis of Adverse Event Reports
Nine pharmaceutical companies independently executed the analyses described below using data extracted from their global safety database. Events reported (initial receipt date) from January 1, 2014, to December 31, 2016, were included in this analysis by 7 of the pharmaceutical companies. One company included reports from May 1, 2016, to July 31, 2017. The ninth company included reports from an unspecified 12-month period. The different time periods used for the collection of data was attributable to the fact that the capability to differentiate between solicited and spontaneous data sources as well as types of data source had been implemented at different times by the participating companies. The need to do so in most company safety databases has only been recently recognized. All 9 companies analyzed PSPs and MRP data. Seven companies analyzed social media data. All analyses and results were collected and blinded by the third party. Blinded results were then reviewed only by 2 member company personnel (the "Firewalled Personnel") who had signed nondisclosure agreements ("NDA") preventing them from sharing the underlying analyses and data with anyone else, including individuals at the Firewalled Personnel's own companies. The NDAs were put in place to ensure confidentiality of adverse event data.
Where extraction was possible, each pharmaceutical company included in their analysis the following data fields from their global safety database:
MedDRA Higher Level Group Term (HLGT) Case type: spontaneous, solicited, patient support program, market research program, or social media Event seriousness: serious or nonserious Product maturity: time on market expressed as either >5 years or 5 years Patient exposure: expressed as patient-years (taken from most recent Periodic Safety Update Report)
HLGT was chosen to keep the volume of data to a size that could be analyzed within a reasonable, iterative time scale and to enable generation of large-scale patterns of patient safety in the data. The proportion of events were calculated for each HLGT value. The numerator of the proportion was defined as the number of reported events in the specific HLGT. The denominator of the proportion was defined as the total number of events for the product across all HLGT. Table 1 describes the proportion calculations each pharmaceutical company tabulated using its own safety information:
Graphs as described below were generated for each subgroup, with subgroup defined as:
1. Patient support program and patient assistance program 2. Market research program 3. Social media Exact Clopper-Pearson confidence limits for the proportion of serious and nonserious subgroup and spontaneous events were calculated for each HLGT. Forest plots were generated of the proportion and 95% confidence interval for serious subgroup and spontaneous events by HLGT. Forest plots were generated for the proportion and 95% confidence interval for nonserious subgroup and spontaneous events by HLGT. Plots were sorted in descending order and truncated when the proportion was <1% for both subgroup and spontaneous events. Eight companies completed the forest plots.
Butterfly plots for the proportion of serious and nonserious subgroup and spontaneous events were generated. Plots were sorted in descending order and truncated when the proportion was <1% for both subgroup and spontaneous events. Nine companies completed the butterfly plots.
In the butterfly plots (Figure 1 ), the y-axis is the MedDRA HLGT classification, ordered according to the most frequent to least frequently reported HLGT. The x-axis indicates the proportion of all reports for that drug falling within each category. If there were a different pattern of data collection between spontaneous and solicited sources, we would expect to see 1 or more bars emerging on one side of the graph that is not reflected by a bar on the other side of the graph. Instead, we found the graphics generally appeared like the sample below: symmetrical responses on both sides of the graphics, with only small differences in the percentage of reports by source. We noted this same pattern regardless of length of time on market, product therapeutic area, or whether we examined at SOC, HLGT, HLT, or PT levels. A similar consistency was noted in the other visual representations of data across companies.
The counts of events at the HLGT level were summarized on a scatter plot comparing spontaneous and solicited counts. The correlation coefficient was computed to compare strength of association of spontaneous event counts and solicited event counts. Additional correlations were computed comparing spontaneous events to the subgroup events. Any HLGT that contained at least 1 observation was included in this analysis. Eight companies completed the scatter plots. HLGTs were identified for which spontaneous case counts were equal to 0. For each HLGT where the spontaneous case count was 0, the number of subgroup cases were summed. This analysis was performed for serious cases and all cases (serious and nonserious) included in this study.
vigiGrade Analysis of Adverse Event Reports
Nine pharmaceutical companies independently executed the analyses described below using data from their global safety database. Events reported (initial receipt date) from January 1, 2014, to December 31, 2016, were included in this analysis by 7 of the pharmaceutical companies. One company included reports from May 1, 2016, to July 31, 2017. The ninth company included reports from an unspecified 12-month period.
All nine companies analyzed patient support program and market research program data. Seven companies analyzed social media data. All results were collected and blinded by the third party. Blinded results were then reviewed only by the Firewalled Personnel.
Where extraction was possible, each pharmaceutical company included in their analysis the following data fields from their global safety database: Comments and free-text information The vigiGrade scoring system was used for this analysis. 6 vigiGrade is a scoring system developed by the Uppsala Monitoring Centre to grade the completeness of clinically relevant information contained within a report. This measure of completeness is independent of whether the information establishes a causal relationship between products and events.
Each participating company scored the cases contained in their safety database in accordance with the algorithms developed by Bergvall et al. 6 In their paper, the vigiGrade scoring system contains multiple checks of fields for complete information. One of the checks requires that the comments field must be manually reviewed for informativeness. To produce results in a timely and efficient manner and avoid manual scoring, an algorithm for this aspect of completeness was developed using the average length of an English sentence and word and was applied to the comments field.
An informative comment consists of at least 3 sentences. 7 The average number of words in an English sentence is 18. 8 There are 3Â18¼54 spaces between words in 3 sentences. The average length of an English word is 5 characters.
Therefore, if applicable, an informative comment was categorized as greater than or equal to 324 characters long (3x18x5¼ 270 nonspace characters plus 54 spaces). All other criteria were scored as described in the original Bergvall et al 6 publication.
Descriptive statistics were calculated and visualizations of the vigiGrade scores were completed to examine the differences between spontaneous and subgroup (patient support program, market research program, and social media) cases using the following analyses:
1. Mean, median, 25th percentile, 75th percentile, minimum, maximum, and 95% confidence interval for the mean 2. The number and percentage of "well-documented" cases (vigiGrade score >0.80) 3. The number and percentage of cases at each of the vigiGrade deciles (0.0-1.0)
The vigiGrade scores were calculated based on the following subgroups:
1. Case type: spontaneous, patient support program and patient assistance program, market research program, or social media 2. Event seriousness: serious or nonserious 3. Report source: physician or patient/consumer report A subsequent vigiGrade analysis was performed according to the above methodology by 6 member companies who were able to separate the combined PSP-PAP subgroup into 2 individual subgroups, that is, one subgroup for PSPs and one subgroup for PAPs.
Results
Signal and Label Change Evaluation
Across the 11 responding companies, an estimate of over 1,091,936 PSP-PAP cases, 50,026 MRP cases, and 33,738 social media cases were analyzed from January 1, 2014, to December 31, 2016, for a total of over 1,175,700 cases across all 3 categories. Some companies did not respond with the number of cases analyzed. Additionally, some companies responded with estimates of analyzed cases, leading to an estimated minimum number of cases reported here. Specifically, 7 companies provided the case count for PSP-PAPs. Six companies provided the case count for MRPs and social media. One additional company provided only the total case count across all 3 categories. A total of 3 companies were unable to respond with case or event count. One of these 3 companies does not categorize cases or events by data source. Two companies did not disclose the case or event count because of company data protection policies.
Companies were asked to identify any valid signals, confirmed signals, and label updates that resulted from analysis of cases from PSP-PAP, MRP, or social media. Across the 3-year period, 9 valid signals and 0 confirmed signals were identified from PSP-PAP, MRP, or social media cases. None of the valid signals identified were confirmed or resulted in a label or Core Company Data Sheet update.
Of the 9 valid signals, 4 were from PSP-PAPs, 4 were from social media, and 1 was unable to be classified as the program was unable to be categorized as a singular solicited subgroup. The valid signals were not confirmed owing to a variety of reasons. When additional information from epidemiology, medical review, etc. was taken into account, the signal was refuted. One valid signal from PSPs contained relevant prior medical history or an event trigger in the majority of cases and the annualized incidence rates were consistent with the background rate from the literature and epidemiologic data. Three valid signals from social media cases were refuted when additional information was reviewed. The last valid signal from social media was confounded by indication and was refuted when additional information was included in the analysis. The company identifying the ninth valid signal stated that it was unable to be classified and did not provide reasons it was unconfirmed to retain confidentiality.
Although no drug safety label changes were identified in response to safety information gathered from PSP-PAPs, MRPs, and social media from the surveyed period, during routine monitoring one company found a valid signal identified through analysis of aggregate data, including cases from spontaneous sources as well as PSP-PAPs leading to a Core Company Data Sheet update. When broken down into PSPs and PAPs, an estimated 70% of the postmarketing cases that contributed to the signal identification were reported from various PSPs involving HCPs ( Table 2 ). The remaining estimated 30% of postmarketing cases were reported from PAPs. There were various types of PSPs that contributed cases to the signal; however, the majority of cases came from a single PSP that aimed to provide patients with education and support via a registered nurse in a call center and if required, an in-person visit. Additionally, the product has been on the market for less than 5 years, thus still with an evolving safety profile.
In summary, 1,253,310 cases reported from PSP-PAPs, MRPs, and social media over a 3-year period reviewed in conjunction with ongoing routine surveillance lead to only 1 drug safety label update, which was identified through routine aggregate analysis of spontaneous, PSP, and PAP cases. For this signal, an estimate of 70% of the postmarketing cases contributing to signal identification were reported from PSPs involving HCPs. No such drug safety label updates were identified through cases reported from MRPs or social media.
Similarity Analysis
Over 41 products were included in the similarity analysis across 9 participating companies. These 41 products yielded 576,031 cases and 1,253,310 events ( Table 3 ). The same 6 companies provided the number of products analyzed, case counts, and event counts. One company did not provide case or event counts as the adverse events were not categorized by data source in the database. Two companies did not disclose case or event counts due to company data protection policies. This led to the minimum number reported here. This pool of cases and events is separate from the signal and label change evaluation; however, there may be some cases and events from this analysis that were evaluated as part of the signal and label change evaluation.
Products included in this analysis were chosen by participating companies for a variety of reasons. A commonly cited reason was that the product was the source of a high number of reported adverse events. A closely related reason was that the product was rich in reports from PSP-PAP, MRP, or social media and provided a balanced view between spontaneous and each solicited data source. Products represented a wide range of therapeutic areas (eg, oncology, cardiovascular, immunology, or central nervous system). Some products have been on the market for a considerable amount of time (eg, more than 50 years), while others were newly launched or early in their life cycle. A large portfolio of products representing a broad spectrum of time on the market was chosen to ensure an analysis was performed on representative data, for example, to determine if there were differences in profiles dependent on duration of the product on the market and/or therapeutic area. While individual results from member companies varied, there are overall trends that can be identified. Generally, PSP-PAPs, MRPs, and social media reported similar proportions for HLGT as with spontaneous sources. Only 1 company (representing 7% of analyzed cases) found that the solicited data sources did not generally follow the same pattern as spontaneous sources. The other 8 companies found varying degrees of proportion similarity, but all found an overall similar pattern of proportionality for HLGTs between the solicited data sources and spontaneous sources. Another key trend between the solicited and spontaneous data sources was that serious events tended to display a higher pattern similarity than nonserious sources.
An additional question to be addressed was whether the solicited data sources were capturing any adverse events that were not being captured by spontaneous sources. To determine this, all HLGTs reported by the solicited sources that were not reported by spontaneous sources were identified. Each of the participating companies found that less than 1% of HLGTs had more than 10 reported cases where spontaneous sources reported none, indicating that these solicited sources generally did not present a trend to capture any information that spontaneous sources did not.
In conclusion, across over 1,320,000 events, PSP-PAPs, MRPs, and social media generally tended to report similar proportions for HLGTs as spontaneous sources. Moreover, the solicited sources generally did not capture any adverse events that spontaneous sources did not.
vigiGrade Analysis
The same cases used in the similarity analysis were analyzed across the same 9 companies to determine their respective vigiGrade scores (Table 3 ). TransCelerate selected vigiGrade to measure case completeness as a surrogate for case quality, allowing each member company to score its respective ICSRs. As evidenced by box and whisker plots and histograms of vigiGrade score, MRPs and social media consistently demonstrated very low vigiGrade mean and median scores. A vigi-Grade score of 0.8 was considered well documented. 7 The mean and median vigiGrade scores seen with both serious and nonserious cases from MRPs and social media rarely reached higher than 0.5 and was commonly observed at a much lower score. Conversely, the mean and median scores of the PSP-PAP subgroup tended to be higher, and appeared to be comparable to spontaneous data. Of note, the range of scores was much larger for PSP-PAPs and spontaneous sources than MRPs and social media, often reaching above 0.8. In fact, the histograms appeared nearly identical between the PSP-PAP subgroup and spontaneous data across the majority of company analyses. Additionally, there was remarkable consistency across company analyses for the MRP and social media histograms. Generally, this information provides some objective evidence that MRPs and social media display a lower vigiGrade score (are less complete) than the cases from PSP-PAP subgroup and spontaneous sources.
To evaluate any potential differences between the various PSP-PAP program subtypes included in the broader category, the subgroup cases were split into 2 categories, PAPs and all other PSPs. The vigiGrade assessed for each subcategory and compared to the scores from spontaneous sources. Six of the 9 companies that performed the previous vigiGrade analysis were able to differentiate PAPs from the broader PSP category. The primary reason for the reduced number of participating companies is the difference in safety database structure and differing classification conventions across different companies. Three of the 6 participating companies observed consistently lower vigiGrade scores for PAPs when compared to PSPs and spontaneous sources. The lower vigiGrade scores were most clearly observed in histograms. The proportion of welldocumented cases (vigiGrade score greater than 0.8) was lowest for PAPs, followed by PSPs. Spontaneous sources demonstrated the highest proportion of well-documented cases. Two of the remaining 3 companies observed highly variable vigiGrade scores of PSPs and PAPs that was dependent on product or program compared to relatively consistent vigi-Grade scores for spontaneous sources. Only one of the 6 companies observed indistinguishable vigiGrade scores between spontaneous sources, PSPs, and PAPs.
Overall, the vigiGrade analysis indicates that reports from MRPs and social media cases display very low completeness or "quality" score and that this finding was highly consistent across all 9 participating companies. Additionally, it was determined that when broken into separate subgroups, PAPs and PSPs displayed a wide range of variability in quality that was dependent on specific product or program.
Discussion
TransCelerate performed both comparative and qualitative analyses across numerous pharmaceutical companies evaluating patient support programs or patient assistance programs, market research programs, and social media to assess the contributions of each data source to patient safety. We evaluated whether any safety label updates resulted from valid and confirmed signals, similarity of safety information reported, and quality of safety information reported. We found that only 1 drug safety label update was identified through routine aggregate analysis of spontaneous and PSP cases, in a setting where most patients on treatment were participating in a PSP or PAP. Additionally, the product recently reached the market (ie, less than 5 years on the market). No drug safety label updates were identified from either MRPs or social media. Generally, we found that PSP-PAPs, MRPs, and social media provide similar proportions of AEs reported by HLGT vs spontaneous reporting mechanism. Lastly, while MRPs and social media displayed very low quality, PSPs and PAPs demonstrated a high degree of variability in quality.
One important limitation of this study is that it was not possible to publish detailed information on individual cases and events since much of the supporting data are likely to contain confidential or private personal health information. In addition, the individual companies that participated in this study collected and analyzed data that is company confidential information and were thus unable to share detailed data with each other. To ensure scientific robustness and to facilitate the study, a third-party management consultant was contracted by TransCelerate to independently assess each company analysis according to the established and agreed methods and confirm the findings. If the analyses did not adhere to the above methods, the analyses were redone until adherence was verified by the third party. While this may be a limitation of this study, the detailed data gathered here would be readily submitted to regulatory authorities on request for further confirmation and review.
Additionally, another limitation of this study is that only MAH patient support programs were included in the analysis, as opposed to PSPs administered by patient advocacy organizations. An area of future research would be to assess the contribution of PSPs administered by patient advocacy organizations to the patient safety monitoring environment.
Despite these limitations, the results indicate that market research programs and social media may not be appropriate for use in safety surveillance. This finding was not unexpected as MRPs and social media were not designed nor intended to capture and report safety information. The safety data that is collected is highly unstructured and is often unconfirmed by an HCP. While MRPs may contain contact information, social media does not and despite the contact information collected by MRPs, the likelihood to receive follow-up information is low. In particular, in some countries and regions, further follow-up is not permitted per local guidance. Because of this extremely low quality, even if the data from these sources were to indicate the identification of a safety signal, the information contained within the cases would generally be insufficient to evaluate the signal. This would lead to an environment where safety data collection would be unable to generate confirmed safety signals, essentially being unable to produce verifiable safety insights. In addition, one may argue that the signal-to-noise ratio is decreasing when the proportion of noninformative cases increases, compared to the proportion of spontaneous, and more informative, case reports. While this study did not demonstrate that social media, MRPs, and PAPs contribute meaningfully to patient safety monitoring, in the future, further refinement of these findings may yield contributions not found here.
In September 2014, the Innovative Medicines Initiative (IMI) initiated a project called Web-RADR to determine and develop the most appropriate use of social media and digital technologies in pharmaceutical research and development. 9 This initiative has found that there is little benefit to collecting individual, valid ICSRs from social media and that requirements should likely be similar to using social media as a secondary source of data with little need for follow-up. However, despite this overall finding, Web-RADR identified that social media might provide benefits when analyzed in aggregate in areas such as abuse or misuse. Additionally, any new safety information identified that impacts the risk-benefit analysis should be reported in accordance with EU GVP Module VI. The findings reported in this paper on social media corroborate the findings and recommendations from the IMI Web-RADR initiative.
Similar to MRPs and social media, PSPs and PAPs are also not designed to collect safety information and, as a result, generally provided no additional opportunities to better understand the safety profile of the products studied. However, unlike MRPs and social media where the quality was consistently very low, the quality of PSPs was highly variable. In certain analyses, the quality appeared to be comparable to spontaneous sources and, in other examples, the quality was low (ie, comparable to MRPs or social media). A key factor that may have contributed to the highly variable quality of PSPs and PAPs compared to MRPs and social media is the broad range of program types all considered to be included in the PSP definition. As such, based on program design and objectives, the adverse event reports from some programs may contribute more meaningfully to safety surveillance activities than others. This hypothesis appears to be supported by the finding from half the companies (ie, those companies able to evaluate PAP quality vs other PSP data sources) that the lower completeness and quality scores related to cases that originated from PAPs. Overall, the design of PSP programs range from face-to-face HCP visits and use of call centers to patient reimbursement programs, and even delivery of medicines. In practice, the variability of PSP design across different countries and regions is extensive. These different types of PSP-PAPs have different characteristics in terms of their scope and structure that could impact the quality and informativeness of data received. For example, adverse events reported through face-to-face HCP visits have the ability to be evaluated, confirmed, and reported by the HCPs at the time of the visit. Conversely, no such evaluation and confirmation are likely to be provided during a contact for a reimbursement program. This higher quality and completeness of information derived from certain PSPs assessed in this study could have been influenced by the higher quality of some subtypes of PSPs, such as those programs that do not involve direct and regular interaction with HCPs such as PAPs. The data appear to demonstrate that not all PSPs are created equal and that this could form the basis for considering a revised, more risk-based (proportionate) approach to managing and analyzing information from all the data sources assessed in this study, with a focus specifically on social media, MRPs, PAPs, and PSPs with lower levels of HCP contact.
Such a risk-based approach would also address one of the acknowledged main limitations of a recent publication by the US FDA 10 that compared data from industry-sponsored programs (eg, PSP, PAP, MRP, etc) to non-industry sponsored program reports from the FAERS database. While this study demonstrated no overall differences between the 2 data sources with regard to usefulness of information for signal detection purposes, it was not designed to determine the quality of safety information from each industry-sponsored program type.
Thus, for pharmacovigilance purposes, suggestions have been made to adopt evidence-based simplification of the current regulatory guidelines with respect to PSPs. 11 The present study provides such evidence, particularly as it was generated consistently across 9 participating member companies of TransCelerate in an anonymized fashion involving a thirdparty evaluator. It has assessed the relative utility of safety information available in a variety of selected data sources, including certain types of PSPs and corroborates external findings that show that appropriate risk-based approaches to managing safety information from these sources could be a pragmatic and evidence-based means to ensure an effective and efficient patient safety monitoring environment.
Conclusions
This study appears to indicate that certain data sources such as MRPs, social media, and PAPs provide data of lower completeness than other PSPs and traditional spontaneous reports, as well as provide no new information over and above traditional methods in place for more than 50 years. The current underlying postmarketing patient safety monitoring system remains state of the art and is likely not improved by the collection of these data sources. On this evidence base it may be possible to take a more risk-based approach to data collection from these sources as opposed to the "one size fits all" standard of reporting all adverse events as individual safety cases currently stipulated by regulatory guidance. Such an approach would clearly require further discussion and consideration between the appropriate stakeholders. Indeed, this evidence is currently being used to open discussions with regulatory authorities such as EMA. 12 In June 2019, the ICH Assembly decided to begin work to update "the existing ICH E2D Guideline to incorporate pragmatic potentially risk-based approaches of the management of information from existing and any new data sources, to enable a greater focus on the data sources that will optimize signal detection activities and public health." 13 For PSPs (other than PAPs) a nuanced approach is likely to be needed because of the variable and disparate range of programs all considered a part of this data source. In line with the risk-based approaches proposed to other solicited programs, we propose that a risk-based approach should be developed that focuses on PSP sources that are designed to be an organized data collection system, that are the most likely to generate medically meaningful information, that will contribute to signal detection and identification of new adverse effects, and that are complementary to traditional spontaneous data sources. Several aspects for a risk-proportionate classification to safety data collection would include the extent and the potential for longitudinal, direct, 2-way HCP contact and communication in the program (eg, regular nurse visits to administer and supervise injections, the anticipated proportion of patients using the product who are enrolled in the PSP, incidental events vs expression of suspicion, the extent of patient exposure, the time on the market or level of maturity of the safety profile, etc).
This work was motivated by a commitment to develop a more effective and beneficial patient safety monitoring environment. This development is a continuous process that evolves as the pharmaceutical industry and the environment changes. We must always ensure that patient safety is the first priority of pharmacovigilance. The recommendations proposed here are intended to adhere to this principle: understanding the relative contributions of each source of information to ensure and improve the safety of patients. An examination of the pertinence of the information gathered and presented here is necessary to ensure that these recommendations improve the patient safety monitoring environment.
